SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.
Börse SIX Swiss Exchange Zürich
ISIN CH0012032113
CHF
  • Roche
    Börse SIX Swiss Exchange Zürich
    ISIN CH0012032113
    CHF
  • Roche
    Börse SIX Swiss Exchange Zürich
    ISIN CH0012032048
  • Roche
    Börse SIX Swiss Exchange Zürich
    ISIN CH0012032048 WKN: 855167
    Symbol ROG
  • Roche
    Börse SIX Swiss Exchange Zürich
    ISIN CH0012032113 WKN: 851311
    Symbol RO
  • Roche
    Börse Börse München
    ISIN CH0012032048
    Symbol RHO5
    EUR
  • Roche
    Börse Tradegate System der Deutsche Börse AG (60%)
    ISIN CH0012032048
    Symbol RHO5
    EUR
  • Roche
    Börse Börse Hamburg
    ISIN CH0012032048
    Symbol RHO5
    EUR
  • Roche
    Börse Gettex System der Börse München
    ISIN CH0012032048
    Symbol RHO5
    EUR
  • Roche
    Börse Börse Düsseldorf
    ISIN CH0012032048
    Symbol RHO5
    EUR
  • Roche
    Börse Quotrix System der Börse Düsseldorf
    ISIN CH0012032048
    Symbol RHO5
    EUR
  • Roche
    Börse Börse Berlin
    ISIN CH0012032048
    Symbol RHO5
    EUR
  • Roche
    Börse Börse Stuttgart
    ISIN CH0012032048
    Symbol RHO5
    EUR
  • Roche
    Börse Börse Frankfurt
    ISIN CH0012032048
    Symbol RHO5
    EUR
  • Roche
    Börse Börse Hamburg
    ISIN CH0012032048
    Symbol RHO
    EUR
  • ROCHE HOLDING AG-BR
    Börse Börse Düsseldorf
    ISIN US771196BJ08
    Symbol RHO
    EUR
  • ROCHE HOLDING AG-BR
    Börse Tradegate System der Deutsche Börse AG (60%)
    ISIN US771196BP67
    Symbol RHO
    EUR
  • ROCHE HOLDING AG-BR
    Börse Quotrix System der Börse Düsseldorf
    ISIN US771196BB71
    Symbol RHO
    EUR
  • ROCHE HOLDING AG-BR
    Börse Gettex System der Börse München
    ISIN US771196BK70
    Symbol RHO
    EUR
  • Roche
    Börse Amerikanscher Freiverkehr OTC oder "Pink Sheets"
    ISIN CH0012032048 WKN: 855167
    Symbol ROG
    USD
  • Roche
    Börse Amerikanscher Freiverkehr OTC oder "Pink Sheets"
    ISIN US771196BE11
    Symbol ROG.SW
    USD
  • ROCHE HOLDINGS INC 144A
    Börse Amerikanscher Freiverkehr OTC oder "Pink Sheets"
    ISIN US771196BM37 WKN: 855167
    Symbol RO
    USD
  • Roche
    Börse Amerikanscher Freiverkehr OTC oder "Pink Sheets"
    ISIN US771196BH42
    USD
  • Roche
    Börse SIX Swiss Exchange Zürich
    ISIN US771196AU61
  • Roche
    Börse Freiverkehr OTC
    ISIN CH0012032048
  • Roche Holding AG
    Börse Freiverkehr OTC
    ISIN US771196BR24
  • Roche Holding AG
    Börse Freiverkehr OTC
    ISIN US771196BL53
  • Roche Holding AG
    Börse Bolsa Mexicana de Valore Mexiko-Stadt
  • Roche Holding AG
    Börse London Stock Exchange
  • Roche Holding AG
    Börse London Stock Exchange
  • Roche Holding AG
    Börse SIX Swiss Exchange Zürich
ISIN CH0012032113
Firmenname Rogers Corporation
Marktkapitalisierung 72.510.514.181 (+- 195%)

Die einen sagen so, die anderen so... Es gibt 3 Datenquellen:

3.554.943.744 oder 406.000.000 oder 213.570.598.800

Mitarbeiter 53.482 (+- 94%)

Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:

3.350 oder 103.613 Mitarbeiter

Anzahl Aktien 862.563.000
KGV 35.97 (+- 46%)

Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:

52.44 oder 19.5

EBITDA 206.224.000
PEGRatio 0.7382
Buchwert 55.625

Zahlte zuletzt am 18.03.2021 eine Dividende von 9,1  . Seit damals wurde keine Dividende mehr ausgeschüttet Übersicht

Roche läuft ähnlich wie der DAX (2.23 %) (+3 % Dividenden) vom 30.09.2013 bis 07.01.2015

Analystenmeinungen

Übersicht

Letzte Communitymeinungen

Ein User hat Roche abonniert.

Aktionärsstruktur der Rogers Corporation

77 News & Informationen zur Roche Aktie

  • These OTC Securities Had the Most Trading Activity in July - Netlist (NLST), Roche Holding Basel (RHHBY)
    benzinga.com

    These OTC Securities Had the Most Trading Activity in July – Netlist (NLST), Roche Holding Basel (RHHBY)

    Photo by Federico Beccari on Unsplash

    In July, O…

  • Cathie Wood’s ARK Invest Sells for 8
    247wallst.com

  • Will Roche’s Stock Rebound After A 4% Fall Following Its H1 Results?
    forbes.com

    Will Roche’s Stock Rebound After A 4% Fall Following Its H1 Results?

    The stock price of Roche Holding’s ADR reached its all-time high of $48 just last week, before a recent sell-off in the stock, which led to over a 4% drop in its price to levels of $46 currently. Much of this fall came in late last week after the company announced its H1 results.

  • Will Roche’s Stock Rebound After A 4% Fall Following Its H1 Results?
    forbes.com

    Will Roche’s Stock Rebound After A 4% Fall Following Its H1 Results?

    The stock price of Roche Holding’s ADR reached its all-time high of $48 just last week, before a recent sell-off in the stock, which led to over a 4% drop in its price to levels of $46 currently. Much of this fall came in late last week after the company announced its H1 results.

  • Will Roche’s Stock Rebound After A 4% Fall Following Its H1 Results?
    forbes.com

    Will Roche’s Stock Rebound After A 4% Fall Following Its H1 Results?

    The stock price of Roche Holding’s ADR reached its all-time high of $48 just last week, before a recent sell-off in the stock, which led to over a 4% drop in its price to levels of $46 currently. Much of this fall came in late last week after the company announced its H1 results.

  • Will Roche’s Stock Rebound After A 4% Fall Following Its H1 Results?
    forbes.com

    Will Roche’s Stock Rebound After A 4% Fall Following Its H1 Results?

    The stock price of Roche Holding’s ADR reached its all-time high of $48 just last week, before a recent sell-off in the stock, which led to over a 4% drop in its price to levels of $46 currently. Much of this fall came in late last week after the company announced its H1 results.

  • Will Roche’s Stock Rebound After A 4% Fall Following Its H1 Results?
    forbes.com

    Will Roche’s Stock Rebound After A 4% Fall Following Its H1 Results?

    The stock price of Roche Holding’s ADR reached its all-time high of $48 just last week, before a recent sell-off in the stock, which led to over a 4% drop in its price to levels of $46 currently. Much of this fall came in late last week after the company announced its H1 results.

  • Will Roche’s Stock Rebound After A 4% Fall Following Its H1 Results?
    forbes.com

    Will Roche’s Stock Rebound After A 4% Fall Following Its H1 Results?

    The stock price of Roche Holding’s ADR reached its all-time high of $48 just last week, before a recent sell-off in the stock, which led to over a 4% drop in its price to levels of $46 currently. Much of this fall came in late last week after the company announced its H1 results.

  • Will Roche’s Stock Rebound After A 4% Fall Following Its H1 Results?
    forbes.com

    Will Roche’s Stock Rebound After A 4% Fall Following Its H1 Results?

    The stock price of Roche Holding’s ADR reached its all-time high of $48 just last week, before a recent sell-off in the stock, which led to over a 4% drop in its price to levels of $46 currently. Much of this fall came in late last week after the company announced its H1 results.

  • Will Roche’s Stock Rebound After A 4% Fall Following Its H1 Results?
    forbes.com

    Will Roche’s Stock Rebound After A 4% Fall Following Its H1 Results?

    The stock price of Roche Holding’s ADR reached its all-time high of $48 just last week, before a recent sell-off in the stock, which led to over a 4% drop in its price to levels of $46 currently. Much of this fall came in late last week after the company announced its H1 results.

  • Cathie Wood’s ARK Invest Sells for 7
    247wallst.com

  • Is the Next Covid Game Changer a Pill?
    bloombergquint.com

    Is the Next Covid Game Changer a Pill?

    (Bloomberg Opinion) — Vaccines have been game changers in the fight against Covid-19, offering effective protection against even highly contagious and pathogenic strains such as the delta variant.

  • Roche Holding AG (RHHBY) CEO Severin Schwan on Q2 2021 Results - Earnings Call Transcript
    seekingalpha.com

    Roche Holding AG (RHHBY) CEO Severin Schwan on Q2 2021 Results – Earnings Call Transcript

    Roche Holding AG (OTCQX:RHHBY) Q2 2021 Earnings Conference Call July 22, 2021, 08:00 ET Company Participants Karl Mahler – Head, IR Severin Schwan – CEO & Executive Director William…

  • Roche Holding AG 2021 Q2 - Results - Earnings Call Presentation (OTCMKTS:RHHBY)
    seekingalpha.com

    Roche Holding AG 2021 Q2 – Results – Earnings Call Presentation (OTCMKTS:RHHBY)

    The following slide deck was published by Roche Holding AG in conjunction with their 2021 Q2 earnings call.

  • Is the next Covid-19 game changer a pill?
    livemint.com

    Is the next Covid-19 game changer a pill?

    With many in the world still unvaccinated and cases on the rise, we’ll need more than shots to keep the virus at bay. Antiviral pills may fill the gap

  • Roche 1st Half Net Profit Fell Despite Higher Sales; Backs 2021 Outlook -- Update
    marketscreener.com

    Roche 1st Half Net Profit Fell Despite Higher Sales; Backs 2021 Outlook — Update

    By Cecilia Butini

    Roche Holding AG said Thursday that profit for the first half of the year decreased though sales grew, driven by the diagnostics division.

    The Swiss pharmaceutical… | July 22, 2021

  • TAGESVORSCHAU/Donnerstag, 22. Juli (vorläufige Fassung)
    finanzen.net

    TAGESVORSCHAU/Donnerstag, 22. Juli (vorläufige Fassung)

    TAGESVORSCHAU/Donnerstag, 22. Juli (vorläufige Fassung) | Nachricht | finanzen.net

  • EUROPEAN MIDDAY BRIEFING : Stocks Rebound After -2-
    marketscreener.com

    EUROPEAN MIDDAY BRIEFING : Stocks Rebound After -2-

    may result in funds managed or advised by Apollo forming part of the consortium. Anglo American 2Q Production Increased as Restrictions Eased Anglo American PLC on Tuesday reported higher…

  • Do High-Quality International Stocks Have A Place In Your Portfolio?
    entrepreneur.com

    Do High-Quality International Stocks Have A Place In Your Portfolio?

    Nokia (NYSE: NOK), AstraZeneca (NASDAQ: AZN) and ASML Holding (NASDAQ: ASML) are among the most popular non-U.S. developed-market stocks.

  • Global Coronavirus Testing Kits Market Report 2021-2026: RT-PCR, Rapid Diagnostics Test, ELISA Test and Others
    prnewswire.com

    Global Coronavirus Testing Kits Market Report 2021-2026: RT-PCR, Rapid Diagnostics Test, ELISA Test and Others

    /PRNewswire/ — The “Global Coronavirus Testing Kits Market, By Type of Test (Molecular v/s Serological), By Use (Multiple Test v/s Single Test), By Full Test…

  • Missouri County Sounds Alarm; Melbourne Locks Down: Virus Update
    financialpost.com

    Missouri County Sounds Alarm; Melbourne Locks Down: Virus Update

    (Bloomberg) — Health officials in southwestern Missouri asked the state to set up an emergency hospital to handle a surge in delta-variant cases that threatens…

  • Global $140 Bn Over the Counter (OTC) Drugs Markets, Forecast & Opportunities, 2025
    prnewswire.com

    Global $140 Bn Over the Counter (OTC) Drugs Markets, Forecast & Opportunities, 2025

    /PRNewswire/ — The “Global Over the Counter (OTC) Drugs Market, By Product (Cough, Cold, and Flu, Analgesics, Dermatology Products, Vitamins, Mineral, and…

  • Global $140 Bn Over The Counter (OTC) Drugs Markets, Forecast & Opportunities, 2025
    thestreet.com

    Global $140 Bn Over The Counter (OTC) Drugs Markets, Forecast & Opportunities, 2025

    DUBLIN, July 15, 2021 /PRNewswire/ — The “Global Over the Counter (OTC) Drugs Market, By Product (Cough, Cold, and Flu, Analgesics, Dermatology Products,

  • Global Artificial Pancreas Device Systems Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts
    prnewswire.com

    Global Artificial Pancreas Device Systems Market (2021 to 2026) – Industry Trends, Share, Size, Growth, Opportunity and Forecasts

    /PRNewswire/ — The “Artificial Pancreas Device Systems (APDS) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026” report…

  • Precision Medicine Market Size Worth USD 126.14 Billion by 2025 at 12.48% CAGR – Report by Market Research Future (MRFR)
    globenewswire.com

    Precision Medicine Market Size Worth USD 126.14 Billion by 2025 at 12.48% CAGR – Report by Market Research Future (MRFR)

    Precision Medicine Market Insights and Industry Analysis by Therapeutics (Cancer/Oncology, Cardiovascular Disease (CVD), Infectious Diseases, Central…

  • 2 Biotech IPO Stocks You'll Want to Have on Your Radar
    fool.com

    2 Biotech IPO Stocks You'll Want to Have on Your Radar

    They have promising pipeline candidates and should go public soon.

  • Roche Finance Europe BV -- Moody's announces completion of a periodic review of ratings of Roche Holding AG
    markets.businessinsider.com

    Roche Finance Europe BV — Moody's announces completion of a periodic review of ratings of Roche Holding AG

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Roche Holding AGRead the full article at Moody's

  • Roche Holding AG Stock Is Estimated To Be Modestly Overvalued
    gurufocus.com

    Roche Holding AG Stock Is Estimated To Be Modestly Overvalued

    GuruFocus Article or News written by GF Value and the topic is about:

  • Atea Pharma Reports Encouraging Results From Study of Covid-19 Treatment
    marketscreener.com

    Atea Pharma Reports Encouraging Results From Study of Covid-19 Treatment

    By Chris Wack

    Atea Pharmaceuticals Inc. reported positive interim results from the global Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate Covid-19.

    Roche… | June 30, 2021

  • Novartis contends Roche 'unjustly enriched' itself with $210 mln in fees -lawsuit
    financialpost.com

    Novartis contends Roche 'unjustly enriched' itself with $210 mln in fees -lawsuit

    ZURICH — Novartis AG wants Roche Holding AG to return $210 million after accusing its Swiss rival of inappropriately pocketing fees from a 16-year-old patent…

  • Eli Lilly Covid-19 Antibody Drug Shipments Paused Over Variant Concerns
    online.wsj.com

    Eli Lilly Covid-19 Antibody Drug Shipments Paused Over Variant Concerns

    U.S. health officials say the drugmaker’s cocktail isn’t effective against strains that are becoming increasingly common across the country.

  • The FDA's Alzheimer's Mistake Is Already Worsening
    bloombergquint.com

    The FDA's Alzheimer's Mistake Is Already Worsening

    (Bloomberg Opinion) — When the U.S. Food and Drug Administration approved Biogen Inc.'s controversial Alzheimer's drug Aduhelm earlier this month without firm evidence that the drug helps patients, it created concern that other unproven treatments might follow. That scenario is already here.

  • EUROPEAN MIDDAY BRIEFING : Stocks Struggle With -2-
    marketscreener.com

    EUROPEAN MIDDAY BRIEFING : Stocks Struggle With -2-

    Roche: Actemra/RoActemra Gets FDA Emergency-Use Authorization for Covid-19 Treatment Roche Holding AG said Friday that it has received an emergency-use authorization from the U.S. Food and Drug…

  • Toshiba Shareholders Oust Chairman in Landmark for Foreign Activists
    online.wsj.com

    Toshiba Shareholders Oust Chairman in Landmark for Foreign Activists

    Toshiba’s chairman was ousted in a vote at the company’s annual meeting, a milestone in Japanese shareholder activism that followed an uproar over collaboration between the firm’s management and the government to stifle foreign investors.

  • Roche's Actemra gets U.S. FDA approval for hospitalized COVID-19 patients
    financialpost.com

    Roche's Actemra gets U.S. FDA approval for hospitalized COVID-19 patients

    The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the drug Actemra for the treatment of hospitalized COVID-19 adults and…

  • U.S. FDA authorizes drug to treat hospitalized COVID-19 patients
    financialpost.com

    U.S. FDA authorizes drug to treat hospitalized COVID-19 patients

    The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the drug Actemra for the treatment of hospitalized COVID- 19 adults and…

  • Tamiflu-Like Drugs Face Long Odds Against Covid ‘Runaway Train’
    bloombergquint.com

    Tamiflu-Like Drugs Face Long Odds Against Covid ‘Runaway Train’

    (Bloomberg) — The flu fighter Tamiflu is one of the most recognizable antiviral medications in the world — but its weaknesses suggest that devising a similarly simple treatment for Covid-19 will be challenging.

    After spending some $20 billion to develop vaccines at top speed, the U.S.

Schreibe einen Kommentar

Wenn du schon einen Account hast, logge dich ein bevor du den Kommentar absendest.

Galue Account Vorteile
  • Battles

    Messe dich mit der Community in Battles.

  • Badges

    Erhalte Belohnungen für Kommentare, die der Community helfen.

  • Mehr Informationen für alle

    Poste Bilder oder Videos zu Themen und Unternehmen und helf dabei, dass Investoren ein kontroverseres Bild erhalten.

  • Kein Datenrisiko

    Du kannst jederzeit deinen Account löschen und gespeicherte Daten einsehen.

Portrait der Roche Aktie

Das Unternehmen Rogers Corporation aus Schweiz beschäftigt 53.482 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Pharmazeutika, Pharma tätig.

Die Roche Aktie hat inklusive der Dividendenausschüttungen seit dem 30.09.2013 eine Gesamtrendite von 16% erwirtschaftet

Mit einem Streubesitz von lediglich 16,6% ist der free float der Aktie vergleichsweise gering. Ein genauerer Blick in die Aktionärsstruktur könnte nützlich sein um den geringen Streubesitz vielleicht aufzuklären.

Das Unternehmen Rogers Corporation ist in mehr als 91 ETFs enthalten und somit ein eher allgemein bekannter Wert. Der Spitzenreiter UBS ETF (CH) SMI® gewichtet Roche mit 18,52% im ETF.

Es ist auch möglich über Anleihen zu investieren. Hier findest du alle Roche Anleihen auf einen Blick.

Entdecke die 6 ETFs in denen Rogers Corporation am höchsten gewichtet ist Insgesamt in 91 ETFs enthalten

Dir gefallen die Informationen zu Roche?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:

Zu BUX Zero

Dir gefallen die Informationen zu Roche?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:

Zu Trade Republic

Dir gefallen die Informationen zu Roche?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:

Zur Comdirect

Dir gefallen die Informationen zu Roche?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:

Zur ING Diba